BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 704492)

  • 1. Managing infections in immunosuppressed patients.
    Featherstone HJ; Dale DC
    Postgrad Med; 1978 Sep; 64(3):141-4, 147-8. PubMed ID: 704492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comment on: empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials.
    Rolston KV; Bodey GP
    J Antimicrob Chemother; 2006 Aug; 58(2):478; author reply 479-80. PubMed ID: 16698848
    [No Abstract]   [Full Text] [Related]  

  • 3. Host defense abnormalities predisposing the patient to infection.
    Peterson PK
    Am J Med; 1984 May; 76(5A):2-10. PubMed ID: 6372471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antibiotic strategies in the febrile neutropenic patient].
    Marie JP
    Presse Med; 1998 Oct; 27(30):1554-6. PubMed ID: 9810315
    [No Abstract]   [Full Text] [Related]  

  • 5. [Infections in neutropenic patients].
    Berenguer J
    Enferm Infecc Microbiol Clin; 1995 Feb; 13(2):113-20. PubMed ID: 7711117
    [No Abstract]   [Full Text] [Related]  

  • 6. Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study.
    Maschmeyer G; Link H; Hiddemann W; Meyer P; Helmerking M; Eisenmann E; Schmitt J; Adam D
    Cancer; 1994 May; 73(9):2296-304. PubMed ID: 8168033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Choice of empirical therapy and prophylaxis.
    Del Favero A; Bucaneve G; Furno P
    Hematol J; 2004; 5 Suppl 3():S53-8. PubMed ID: 15190279
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of febrile neutropenia episodes in children, with a piperacillin-tazobactam and netilmicin combination].
    Fouyssac F; Salmon A; Mansuy L; Schmitt C; Bordigoni P; Chastagner P
    Med Mal Infect; 2005 Jun; 35(6):357-62. PubMed ID: 15982848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antimicrobial prophylaxis and therapy in neutropenia].
    Link H
    Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
    Bodey GP
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical therapy of infections in neutropenic patients.
    Gaya H
    Br J Haematol; 1998 May; 101 Suppl 1():5-9. PubMed ID: 9607734
    [No Abstract]   [Full Text] [Related]  

  • 12. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
    Pizzo PA
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibiotic strategy for febrile episodes during severe (less than 500 PNN) and prolonged (greater than or equal to 7 days) neutropenia. Recommendations of the Evaluation Committee of the Collège Français des Hematologistes].
    Cordonnier C; Leverger G; Schlemmer B; Andremont A; Boasson M; Herbrecht R; Kazmierczak A; Marie JP; Marit G; Miclea JM
    Nouv Rev Fr Hematol (1978); 1994 Aug; 36(4):289-91. PubMed ID: 7971247
    [No Abstract]   [Full Text] [Related]  

  • 15. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fever in the neutropenic patient].
    Milpied N
    Rev Prat; 2001 Mar; 51(6):633-7. PubMed ID: 11345865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems of studying infections in the compromised host.
    Young LS
    Rev Infect Dis; 1986; 8 Suppl 3():S341-9. PubMed ID: 3529327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fever in patients with neutropenia.
    Rolston KV; Rubenstein EB
    N Engl J Med; 1993 Oct; 329(17):1279-80. PubMed ID: 8413407
    [No Abstract]   [Full Text] [Related]  

  • 20. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.